TY - JOUR
T1 - Neutrophils as immune effector cells in antibody therapy in cancer
AU - Behrens, Leonie M.
AU - van Egmond, Marjolein
AU - van den Berg, Timo K.
N1 - Funding Information: The research performed by Leonie M. Behrens is funded by a grant from Byondis B.V. Publisher Copyright: © 2022 The Authors. Immunological Reviews published by John Wiley & Sons Ltd.
PY - 2022
Y1 - 2022
N2 - Tumor-targeting monoclonal antibodies are available for a number of cancer cell types (over)expressing the corresponding tumor antigens. Such antibodies can limit tumor progression by different mechanisms, including direct growth inhibition and immune-mediated mechanisms, in particular complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and antibody-dependent cellular cytotoxicity (ADCC). ADCC can be mediated by various types of immune cells, including neutrophils, the most abundant leukocyte in circulation. Neutrophils express a number of Fc receptors, including Fcγ- and Fcα-receptors, and can therefore kill tumor cells opsonized with either IgG or IgA antibodies. In recent years, important insights have been obtained with respect to the mechanism(s) by which neutrophils engage and kill antibody-opsonized cancer cells and these findings are reviewed here. In addition, we consider a number of additional ways in which neutrophils may affect cancer progression, in particular by regulating adaptive anti-cancer immunity.
AB - Tumor-targeting monoclonal antibodies are available for a number of cancer cell types (over)expressing the corresponding tumor antigens. Such antibodies can limit tumor progression by different mechanisms, including direct growth inhibition and immune-mediated mechanisms, in particular complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis, and antibody-dependent cellular cytotoxicity (ADCC). ADCC can be mediated by various types of immune cells, including neutrophils, the most abundant leukocyte in circulation. Neutrophils express a number of Fc receptors, including Fcγ- and Fcα-receptors, and can therefore kill tumor cells opsonized with either IgG or IgA antibodies. In recent years, important insights have been obtained with respect to the mechanism(s) by which neutrophils engage and kill antibody-opsonized cancer cells and these findings are reviewed here. In addition, we consider a number of additional ways in which neutrophils may affect cancer progression, in particular by regulating adaptive anti-cancer immunity.
KW - PMN
KW - cancer
KW - immunotherapy
KW - neutrophils
KW - trogocytosis
KW - trogoptosis
UR - http://www.scopus.com/inward/record.url?scp=85141411392&partnerID=8YFLogxK
U2 - https://doi.org/10.1111/imr.13159
DO - https://doi.org/10.1111/imr.13159
M3 - Review article
C2 - 36331258
SN - 0105-2896
JO - Immunological Reviews
JF - Immunological Reviews
ER -